Hansoh Pharmaceutical Group Company Limited
3692
Rangering i aksjer
#972
Hansoh Pharmaceutical Group Company Limited, an investment holding company,... Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Zefei, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Mailingda, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and Saint Luolai, Fulaimei, Ruibote, Fulaidi, Fulairui, Punuoan tablets, etc. It has licence agreements with GlaxoSmithKline Intellectual Property (No.4) Limited to develop, manufacture, and commercialize HS-20089 and HS-20093 for the treatment of patients with extensive-stage small-cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy; Biotheus Inc. to develop, produce, and commercialize bispecific antibody-drug conjugate product; and with Merck Sharp & Dohme LLC (MSD) to develop, manufacture, and commercialize HS-10535, an investigational pre-clinical oral small molecule glucagon-like peptide-1 (GLP-1) receptor agonist. The company was founded in 1995 and is headquartered in Shanghai, China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
Aksjekurs
$4.06
Sist synkronisert: 2026-10-16
Markedsverdi
$24.62B
Endring (1 dag)
1.15%
Endring (1 år)
-13.54%
Land
CN
Handel Hansoh Pharmaceutical Group Company Limited (3692)
Kategori
Healthcare
Driftsmargin for Hansoh Pharmaceutical Group Company Limited (3692)
Driftsmargin per October 2026 TTM: 37.52%
Ifølge Hansoh Pharmaceutical Group Company Limited sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 37.52%. Ved slutten av 2023 hadde selskapet en driftsmargin på 28.10%.
Historikk for driftsmargin for Hansoh Pharmaceutical Group Company Limited fra 2016 til 2026
Driftsmargin ved slutten av hvert år
| År | Driftsmargin | Endre |
|---|---|---|
| 2026 (TTM) | 37.52% | 14.11% |
| 2024 | 32.88% | 17.01% |
| 2023 | 28.10% | -1.30% |
| 2022 | 28.47% | -2.33% |
| 2021 | 29.15% | -8.65% |
| 2020 | 31.91% | -0.34% |
| 2019 | 32.02% | 6.56% |
| 2018 | 30.05% | -3.62% |
| 2017 | 31.18% | -6.28% |
| 2016 | 33.27% | 0.00% |
Driftsmargin for lignende selskaper eller konkurrenter
| Selskap | Driftsmargin | Forskjell i driftsmargin | Land |
|---|---|---|---|
| 0.00% | - |
DE
|
|
| 0.00% | - |
DE
|
|
| 0.00% | - |
JP
|
|
| 0.00% | - |
CH
|
|
| 22.93% | -99.39% |
IN
|
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.